<?xml version="1.0" encoding="UTF-8"?>
<notes notes-type="COI-statement">
 <sec id="FPar1">
  <title>Conflict of interest</title>
  <p>S. van Wetering, S.K. Singh and A.M. Kruisbeek are employees of DCPrime but hold no ownership interests. G.J. Ossenkoppele is a consultant for Novartis, Pfizer, Bristol Myers-Squibb, Johnson &amp; Johnson, Sunesis, Celgene, Karypharm, and Amgen. G.J. Ossenkoppele receives research support from Novartis, Johnson &amp; Johnson, Celgene, Immunogene, and Becton Dickinson. No potential conflicts of interest are applicable to the other authors.</p>
 </sec>
 <sec id="FPar2">
  <title>Ethical approval</title>
  <p>The clinical protocol was approved by the Dutch national ethical authority (NL25661.000.09; EudraCT number 2008-006950-16). Informed consent was obtained from all patients included in the study. All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975 (in its most recently amended version).</p>
 </sec>
</notes>
